![Kiran Nistala](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kiran Nistala
Directeur Technique/Scientifique/R&D chez
ZURA BIO LIMITED
Fortune : 13 739 $ au 31/05/2026
Profil
Kiran Nistala is Chief Medical Officer & Head-Development at Zura Bio Ltd. since 2023.
Dr. Nistala was Vice President at AstraZeneca, Inc. from 2020 to 2023.
Education includes an undergraduate degree from the University of Cambridge in 1993, an undergraduate degree from University College London in 1996, and a doctorate from University College London in 2010.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/04/2026 | 3 195 ( 0% ) | 13 739 $ | 31/05/2026 |
Postes actifs de Kiran Nistala
| Sociétés | Poste | Début |
|---|---|---|
| ZURA BIO LIMITED | Directeur Technique/Scientifique/R&D | 01/11/2023 |
Anciens postes connus de Kiran Nistala
| Sociétés | Poste | Fin |
|---|---|---|
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Manufactures vaccines | Corporate Officer/Principal | 01/10/2023 |
Formation de Kiran Nistala
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
96
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca, Inc.
AstraZeneca, Inc. BiotechnologyHealth Technology Manufactures vaccines | Health Technology |
Zura Bio Ltd.
 Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
